Rua Bioscience has received shareholder approval for their acquisition of Zalm Therapeutics, setting the stage for the company to accelerate their market entry and expand patient choice.
The resolution, which was passed by the required majority, sets out the issue of 8,140,000 new ordinary shares (Initial Shares) and 16,280,000 equity securities that have the right to convert into ordinary shares on achievement of certain milestones (Performance Shares).
See more
